Document is current
Any future updates will be listed below
-
Authors
Guy, Clifford
Mitrea, Diana M.
Chou, Po-Chien
Temirov, Jamshid
Vignali, Kate M.
Liu, Xueyan
Zhang, Hui https://orcid.org/0000-0001-6825-5649
Kriwacki, Richard https://orcid.org/0000-0002-9798-6018
Bruchez, Marcel P.
Watkins, Simon C. https://orcid.org/0000-0003-4092-1552
Workman, Creg J. https://orcid.org/0000-0002-9964-9509
Vignali, Dario A. A. https://orcid.org/0000-0002-2771-5992
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01 AI108545, R01 AI129893, R01 AI144422, R01 AI144422)
- License Information
-
More Information
Article History
Received: 22 October 2020
Accepted: 3 March 2022
First Online: 18 April 2022
Competing interests
: D.M.M. is an employee and stock holder of Dewpoint Therapeutics. D.A.A.V. and C.J.W. have patents covering LAG3, with others pending, and are entitled to a share in net income generated from licensing of these patent rights for commercial development. D.A.A.V. is a cofounder and stock holder at Novasenta, Potenza, Tizona, Trishula; is a stock holder at Oncorus, Werewolf, Apeximmune; has patents licensed and royalties at Astellas, BMS, Novasenta; is a scientific advisory board member at Tizona, Werewolf, F-Star, Bicara, Apeximmune, T7/Imreg Bio; is a consultant at Astellas, BMS, Almirall, Incyte, G1 Therapeutics; has received research funding at BMS, Astellas and Novasenta. The remaining authors declare no competing interests.
